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urothelial carcinoma of the bladder
Joshua R Peck1, Charles L Hitchcock2, Sara Maguire3, Jennifer Dickerson4 and Charles Bush4,5*Abstract: A 57-year-old male with a history of hypertension presented with shortness of breath, intermittent
substernal chest pain, subjective fevers, and a 30-pound weight loss. He was found to have a bladder mass four
months prior to presentation, for which he underwent cystoscopy and surgical removal. Pathology demonstrated
high-grade superficial plasmacytoid urothelial carcinoma extending into the submucosa but not the muscularis
propria. Given the superficial nature of his bladder cancer, a cystectomy was deferred. He was subsequently lost to
follow-up care. On arrival, physical exam was notable for tachycardia, tachypnea, and distant heart sounds. An ECG
showed an incomplete right bundle branch block and sinus tachycardia. Computed tomography pulmonary
angiography revealed a three-cm pericardial effusion. Transthoracic echocardiography confirmed this finding and
revealed a mass in the right ventricle (RV) extending into the outflow tract and infiltrating the free wall. The RV was
dilated with an estimated RV systolic pressure of 37 mmHg. Pericardiocentesis yielded nearly one liter of
serosanguinous fluid with non-diagnostic cytology. Partial median sternotomy with biopsy showed pathologic
findings consistent with metastatic urothelial carcinoma, plasmacytoid variant. A PET scan showed increased uptake
exclusively in the heart. The oncology team discussed options with the patient including chemotherapy and
palliative care. The patient decided to withhold further therapy and went home with hospice care. He died two
months later.
Discussion: Bladder cancer is the fourth most common cancer in men in the United States. Most patients (69%)
with metastatic bladder cancer have multiple organs involved; conversely, our patient had a PET scan indicating his
disease was localized to the heart. Plasmacytoid urothelial carcinoma is a rare subtype of bladder cancer, and is
estimated to make up less than three percent of all invasive bladder carcinomas. At the time of this publication we
are aware of only three other reported instances of isolated cardiac metastasis with urothelial bladder origin; none
of which were the plasmacytoid variant.
Conclusion: This case highlights a previously unreported presentation of plasmacytoid urothelial carcinoma.
Clinicians must remember that even superficial cancers can have significant metastatic potential.
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Urothelial cell carcinoma (UCC) with metastasis exclu-
sively to the heart is an extremely rare and atypical pres-
entation of a relatively common malignancy. A review of
current literature yields only three other instances of this
unusual metastatic pattern [1-3]. We present a 57-year-old
male with plasmacytoid urothelial carcinoma (PUC) of the
bladder and isolated metastasis to the heart. To our* Correspondence: Charles.Bush@osumc.edu
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reproduction in any medium, provided the orknowledge, an isolated cardiac metastasis from this rare
type of UCC has never been reported in the literature.Case report
A 57-year-old male with a past medical history of hyper-
tension, type-2 diabetes and superficial UCC presented
with shortness of breath, substernal chest pain, and
fevers. He was found to have a bladder mass four
months earlier, for which he underwent cystoscopy and
surgical removal. Pathology demonstrated high-grade
superficial PUC extending into the submucosa but not
the muscularis propria. Given the superficial nature ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Cardiac MRI, T1 weighted bright blood imaging axial
orientation.
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subsequently lost to follow-up care.
Upon presentation to our emergency department, the
patient was tachycardic and tachypneic with distant
heart sounds. An electrocardiogram (ECG) showed an
incomplete right bundle branch block and sinus tachy-
cardia. A computed tomography (CT) pulmonary angi-
ography scan revealed a three-cm pericardial effusion.
Transthoracic echocardiography visualized a right ven-
tricular (RV) mass which extended into the outflow tract
and appeared to infiltrate the RV free wall (Figure 1).
A large pericardial effusion was present. The RV was
dilated with an estimated RVSP of 37 mm Hg. There
was no sign of right heart collapse. Subsequent T1
weighted cardiac Magnetic Resonance Imaging (MRI) in
the axial view showed the RV free wall diffusely infil-
trated with tumor extending into the RV cavity and
a large circumferential pericardial effusion (Figure 2).
Pericardiocentesis yielded nearly one liter of serosangui-
nous fluid with non-diagnostic cytology. A whole body
Positron Emission Tomography (PET) scan showed
increased uptake exclusively in the heart (Figure 3).
A mini sternotomy with biopsy showed infiltrating
tumor cells with a plasmacytoid appearance and a strong
desmoplastic response (Figure 4). Immunohistochemical
staining demonstrated tumor cells consistent with meta-
static PUC.
The oncology team discussed options including
chemotherapy, palliative surgical debulking, and comfort
care. The patient decided to go home with hospice. He
died two months later.
Discussion
Our discussion highlights the uniqueness of bladder can-
cer metastasizing to the heart and explores the rareFigure 1 Transthoracic Echocardiogram in a Parasternal Long
Axis View showing a Large Pericardial effusion and RV Mass
Large Pericardial effusion and RV Mass.subtype of PUC. Bladder cancer is the fourth most com-
mon cancer in men in the United States [4]. Normal pat-
terns of metastasis typically follow a predictive pattern,
first involving regional and juxtaregional lymph nodes,
then liver, lungs, bones, and less commonly intestine,
adrenal glands and kidneys [5]. Most patients (69%) with
metastatic bladder cancer have more than one organ
involved [6]. Cardiac metastases are much less common,
with the first case reported in 1967 [7]. At the time of
this publication we are aware of only three other
reported instances of isolated cardiac metastasis from
urothelial cell carcinoma [1-3].
Metastases to the heart and pericardium are inciden-
tally discovered at autopsy in 10%–12% of patients withFigure 3 PET scan showing intense uptake in the myocardium
(arrow).
Figure 4 Right Ventricular Mass Biopsy.
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to have cardiac metastasis found at autopsy include
pleural mesotheliomas (48.4%), melanomas (27.8%), lung
adenocarcinomas (21%), and undifferentiated carcin-
omas (19.5%) [9]. It is very rare for malignancies to have
solitary cardiac metastasis, with post-mortem studies
finding rates of only 0.015%.
PUC is a rare and only recently described type of blad-
der cancer, with the first reported case in 1991 [10]. It isBladder- CK7 Immunohistochemical
staining of invading tumor cells 40x 
Bladder- CD 138 staining of  
tumor cells 40x
Figure 5 Bladder Mass Biopsy.estimated to make up less than three percent of all inva-
sive bladder carcinomas [11]. Although it is still a rela-
tively new entity, data thus far has demonstrated that
PUC is an aggressive tumor with extensive local growth
and poor prognosis [12].
The histopathology of PUC is characterized by invasive
discohesive growth of plasmacytoid cells with eccentric
nuclei. The normal immunohistochemical staining pat-
tern for urothelial carcinomas is variable. CytokeratinBladder- H & E stained invading tumor 
cells 40x 
High Molecular Weight Keratin 
(HMWK) staining of tumor cells  
40 x
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whereas as the CK20 expression varies from 15% to 97%
depending on the study [13]. PUC cells stain with CK,
epithelial membrane antigen, GATA binding protein 3
(endothelial transcription factor 3), cluster of differenti-
ation (CD) 15, CD138, protein 53 (p53), and protein 16
(p16) [14-16].
A review of hematoxylin and eosin (H&E) stained sec-
tions of the biopsied primary tumor demonstrated an
invasive urothelial carcinoma with discohesive epithelial
cells and plasmacytoid features (Figure 5). Subsequent
immunohistochemical staining demonstrated positive
cytoplasmic staining for pankeratin anion exchanger 1
and 3 (AE1/AE3, not shown), high molecular weight
keratin (HMWK), CK7, and positive cell surface staining
for CD138. All of the tumor cells had this staining pat-
tern. The same cells were seen in the cardiac biopsy
(Figure 4) along with a prominent desmoplastic response
not seen in the primary tumor. Immunohistochemical
staining of the cardiac biopsy demonstrated positive
staining for AE1/AE3, HMWK, CK7, and CD138.
Although not performed on the primary tumor, the
metastatic cells lacked staining for CK20, muscle-
specific actin (HHF-35), myogenin, desmin, calretinin,
the monoclonal antibody D2-40, Wilm’s tumor gene
(WT-1), Melan-A, protein S-100, Human Melanoma
Black (HMB-45), and CD45.
In general, the differential diagnosis for a CK7 positive
and CK20 negative tumors include urothelial carcinoma,
breast carcinoma, ovarian serous carcinoma, mesotheli-
oma and prostatic carcinoma. In this case, the differen-
tial diagnosis is narrowed to urothelial carcinoma,
mesothelioma and prostatic carcinoma. There was no
clinical or radiographic evidence of mesothelioma, nor
was there positive staining of the metastatic tumor for
the mesothelial markers calretinin, WT-1, and D2-40.
High molecular weight cytokeratin is highly sensitive
marker for urothelial carcinomas and helps distinguish it
from prostate carcinoma which lacks HMWK expression.
Cardiac magnetic resonance imaging was conducted to
further image the myocardium to obtain information
regarding the histopathologic composition of the tumor
as well as to evaluate for any adverse hemodynamic
effects. Cardiac MRI is superior for assessment of tumor
morphology to assist with mass characterization. While
hybrid PET/CT has been used for imaging of solid
organs, this has not been widely used for cardiac im-
aging [17,18].
Metastases from PUC have been reported in adjacent
pelvic structures, bone, and peritoneum. [12,19]. In a
review of the literature, we have not identified any cases
of isolated or non-isolated cardiac metastasis from this
subtype of UCC. It is unknown why there have not been
any other documented cases of metastasis to the heart,however a possible explanation may be that this tumor
is usually spread via direct extension into surrounding
structures rather than hematogenously.
PUC is often discovered at a late stage, which contri-
butes to its poor prognosis. Our patient had a superficial
PUC that did not invade the muscularis propria of his
bladder wall. Conservative treatment was chosen for the
patient based on these findings. Despite removal of any
identifiable whether the initial biopsy report underesti-
mated the staging, or whether tissue had already seeded
the heart. Whole body PET suggested that the PUC did
not persist in his bladder and had not metastasized to
any other sites. Such findings point to the need for more
aggressive interventions and close follow-up for patients
with the plasmacytoid variant of UCC, regardless of the
degree of tumor infiltration.
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